Since the number of tumor cells expressing PD-L1 greatly influences its ability to suppress immunogenicity and further determines the efficacy of PD-L1 and PD-1 blockade with ICI, PD-L1 expression on tumor cells is a predictive biomarker for ICI therapy (4). This evidence concerns the gene PDCD1 and neoplasm.